Loading clinical trials...
Loading clinical trials...
A Long-term Follow-up Study in Patients Previously Treated With Mustang Bio, Inc. CAR-T Cell Investigational Products
Conditions
Interventions
Prior MB-102 CAR-T cell investigational product.
Prior MB-106 CAR-T cell investigational product.
Locations
5
United States
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Rochester Medical Center
Rochester, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Start Date
September 29, 2021
Primary Completion Date
April 12, 2024
Completion Date
April 12, 2024
Last Updated
July 22, 2024
NCT06006403
NCT04013685
NCT07007052
NCT03599960
NCT03203369
Lead Sponsor
Mustang Bio
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions